Biontech Faces Major Financial Losses and Departure of Founding Duo

Biontech, the biotechnology company renowned for its pioneering work in mRNA technology, has reported a multi-billion euro loss for the fiscal year 2025. In addition to these financial setbacks, the company is set to experience a significant leadership change as its founders, Ugur Sahin and Özlem Türeci, have announced their intention to step down by the end of 2026, coinciding with the conclusion of their current contracts.

The founders, who currently hold approximately 15 percent of Biontech's shares, plan to establish a new biotechnology enterprise that will focus on advancing the next generation of mRNA-based medicines. Although they will relinquish their operational roles, they intend to maintain their stakes in Biontech as shareholders. According to the company, there are plans to transfer intellectual property rights and mRNA technologies to this upcoming venture. In return, Biontech will secure a minority share in the new company and receive milestone payments as well as licensing fees upon the achievement of specific developmental goals. Both companies aim to finalize binding agreements related to this collaboration by the first half of 2026.

Biontech was established in 2008 with an initial mission to develop mRNA-based therapies for cancer. The company gained global prominence during the COVID-19 pandemic by rapidly redirecting its resources to develop an mRNA vaccine against the coronavirus. In partnership with Pfizer, Biontech was among the first to receive regulatory approval for its COVID-19 vaccine, which led to a significant surge in revenue and international recognition. The success of this vaccine also brought numerous awards to the company's founders, highlighting their contributions to medical innovation.

However, in the years following the pandemic, Biontech's revenues and profits have declined sharply, reflecting reduced demand for COVID-19 vaccines. Despite this, the company continues to focus on research and development in the mRNA field, particularly targeting oncological treatments and other medical conditions. Currently, the COVID-19 vaccine remains Biontech's only commercially available product, with ongoing enhancements to address emerging viral variants.

Looking ahead, Biontech is concentrating its efforts on several late-stage clinical trials for cancer treatments. The company's strategic objective is to file multiple regulatory submissions for oncology therapies by 2030, aiming to broaden its portfolio beyond infectious disease prevention and into cancer care. The transition of its founding team and the establishment of a new, innovation-driven biotechnology company are expected to foster additional advancements in mRNA therapies and strengthen Biontech's position in the competitive biotech sector through collaborative synergies.

While Biontech navigates a challenging financial period and prepares for organizational transformation, it remains committed to its long-term research goals, seeking to maintain its reputation as a leader in mRNA-based medical solutions.